Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 31Polycystic Ovary Syndrome 9Breast Neoplasms 8Infertility 7Ovarian Hyperstimulation Syndrome 3Lymphoma 3Sarcoma, Ewing 2Sarcoma 2Prostate Adenocarcinoma 2Osteosarcoma 2Neoplasms 2Uterine Anomalies 1The Neoadjuvant Therapy 1Salpingitis 1Primary Ovarian Insufficiency 1Pregnancy, Ectopic 1Neoplasm Metastasis 1Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel 1Myofibroma 1Metabolic Syndrome 1Leiomyoma 1Infertility, Female 1Hypogonadism 1Hodgkin Disease 1Helping Behavior 1Fatty Liver 1Endometritis 1Endometriosis 1Drug-Related Side Effects and Adverse Reactions 1Castration-resistant Prostate Cancer Patients with Oligometastases 1

Interventions

Triptorelin Pamoate 1Paclitaxel 1Fulvestrant 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × The Neoadjuvant Therapy × Triptorelin Pamoate × Clear all
NCT04753177 2021-02-15

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary

Phase 2/3 Unknown
120 enrolled

The Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡